GlassScriptPhysician profile
Sarah J Cooling
NPI 1457525453
$9,864.77
in general payments reported to CMS, 2019-2025
28 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,531 · 2022: $2,085 · 2023: $2,088 · 2024: $1,934 · 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,149 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,149.27 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,707.84 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,116.80 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,043.16 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $818.93 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $788.82 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $677.19 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $555.93 | 2022-2025 | Auvelity |
| Alkermes, INC. | $474.81 | 2021-2025 | Aristada, Lybalvi |
| Indivior INC. | $363.72 | 2021-2024 | Perseris, Sublocade |
| Lundbeck LLC | $363.05 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $323.85 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $282.34 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $172.84 | 2021 | |
| Novo Nordisk INC | $137.24 | 2021-2022 | |
| Noven Therapeutics, LLC | $136.40 | 2022-2025 | Xelstrym, Secuado |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $125.64 | 2022-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $117.72 | 2024-2025 | Cobenfy |
| Gilead Sciences, INC. | $116.54 | 2022-2023 | Epclusa |
| Glaxosmithkline, LLC. | $112.95 | 2021 | |
| Idorsia Pharmaceuticals US INC | $76.10 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $66.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.66 | 2022-2023 | Belsomra |
| Alfasigma USA, INC. | $34.94 | 2022 | |
| Sage Therapeutics, LLC | $33.41 | 2024-2025 | Zurzuvae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.41 | 2024 | |
| Bausch Health US, LLC | $15.97 | 2022 | |
| Eisai INC. | $14.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cooling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.